Clinical trialNCT05077527RecruitingPhase 1Interventional

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

SponsorAIDS Malignancy ConsortiumEnrollment20AIDS-Related Diffuse Large B-cell LymphomaAIDS-Related Non-Hodgkin LymphomaHIV InfectionRecurrent Diffuse Large B-Cell LymphomaRecurrent Grade 3b Follicular LymphomaRecurrent High Grade B-Cell Lymphoma+9 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase I trial evaluates the side effects and usefulness of axicabtagene clioleucel (a CAR-T therapy) and find out what effect, if any, it has on treating patients with HIV-associated aggressive B-cell non-Hodgkin lymphoma that has come back (relapsed) or not responded to treatment (refractory). T cells are infection fighting blood cells that can kill tumor cells. Axicabtagene ciloleucel consists of genetically modified T cells, modified to recognize CD-19, a protein on the surface of cancer cells. These CD-19-specific T cells may help the body's immune system identify and kill CD-19-positive B-cell non-Hodgkin lymphoma cells.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Ariela Noy
AIDS Malignancy Consortium
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

City of Hope Comprehensive Cancer Center
Duarte, California, United States
John Baird, MD
Recruiting
University of Illinois at Chicago
Chicago, Illinois, United States
Paul Rubinstein, MD
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Maria Palomba, MD
Recruiting
Montefiore Medical Center - Moses Campus
The Bronx, New York, United States
Lauren Shapiro, MD
Recruiting
the Ohio State University
Columbus, Ohio, United States
Polina Shindiapina, Phd,MD,BS
Recruiting
University of Pennsylvania / Abramson Cancer Center
Philadelphia, Pennsylvania, United States
Colin Thomas, MD
Recruiting
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, United States
Margaret K Baron, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Axicabtagene ciloleucel →Cyclophosphamide →Fludarabine →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 13 Feb 2025
Primary completion: 31 Jan 2028
Completion: 31 Jan 2029
Last update posted: 10 Jul 2026
Registered enrollment: 20
Registry id: NCT05077527

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.